FDA-cleared profile

DM-Density

Densitas, Inc. · Mammography/DBT · FDA-cleared (510(k))

DM-Density is a software application intended for use with compatible full field digital mammography systems. DMDensity calculates percent breast density defined as the ratio of fibroglandular tissue to total breast area estimates. DM-Density provides these numerical values for each breast as well as a density category to aid interpreting physicians in the assessment of breast tissue composition. DM-Density produces adjunctive information. It is not a diagnostic aid.

Clinical role
Calculates percent breast density per breast and a density category from full field digital mammography, output as a DICOM Structured Report or Secondary Capture for workstation or PACS viewing; adjunctive information for interpreting physicians, not a diagnostic aid.
Images and patients
Mammography/DBT · Breast
Key limitation
Scanner manufacturers: Hologic/Lorad

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyMammography/DBT · Breast
  • Workflow roleCalculates percent breast density per breast and a density category from full field digital mammography, output as a DICOM Structured Report or Secondary Capture for workstation or PACS viewing; adjunctive information for interpreting physicians, not a diagnostic aid.
  • Required inputDICOM for-presentation full field digital mammograms from compatible digital mammography systems; validated on Hologic Selenia Dimensions and Lorad Selenia systems.
  • Output and human actionFor each breast (BI-RADS 4th Ed.): area of fibroglandular tissue (cm²), area of breast (cm²), area-based breast density (%). For each patient (BI-RADS 4th Ed.): DM-Density breast density grade and percent breast density. For each patient (BI-RADS 5th Ed.): DM-Density breast density grade. Output is delivered as a DICOM mammography Structured Report or Secondary Capture viewable on a mammography workstation or PACS, and may also be transmitted to a RIS.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
DM-Density is a software application intended for use with compatible full field digital mammography systems. DMDensity calculates percent breast density defined as the ratio of fibroglandular tissue to total breast area estimates. DM-Density provides these numerical values for each breast as well as a density category to aid interpreting physicians in the assessment of breast tissue composition. DM-Density produces adjunctive information. It is not a diagnostic aid.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Calculates percent breast density per breast and a density category from full field digital mammography, output as a DICOM Structured Report or Secondary Capture for workstation or PACS viewing; adjunctive information for interpreting physicians, not a diagnostic aid.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DM-Density is a software application intended for use with compatible full field digital mammography systems. DM-Density calculates percent breast density defined as the ratio of fibroglandular tissue to total breast area estimates." … "DM-Density provides these numerical values for each breast as well as a density category to aid interpreting physicians in the assessment of breast tissue composition. DM-Density produces adjunctive information. It is not a diagnostic aid.". Read from the exact FDA decision document on 2026-11-14.

Required input
DICOM for-presentation full field digital mammograms from compatible digital mammography systems; validated on Hologic Selenia Dimensions and Lorad Selenia systems.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DM-Density is a standalone software application that automatically analyzes “for presentation” full field digital mammograms to calculate breast tissue composition." … "DM-Density has been validated on Hologic’s Selenia Dimensions and Lorad Selenia systems.". Read from the exact FDA decision document on 2026-11-14.

Output and clinician action
For each breast (BI-RADS 4th Ed.): area of fibroglandular tissue (cm²), area of breast (cm²), area-based breast density (%). For each patient (BI-RADS 4th Ed.): DM-Density breast density grade and percent breast density. For each patient (BI-RADS 5th Ed.): DM-Density breast density grade. Output is delivered as a DICOM mammography Structured Report or Secondary Capture viewable on a mammography workstation or PACS, and may also be transmitted to a RIS.
  • Exact FDA submission
  • Checked 2026-09-01

Clinical output reported in the exact-submission ACR model card.

Intended users
Interpreting Physicians
  • Exact FDA submission
  • Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Limitations
Scanner manufacturers: Hologic/Lorad
  • Exact FDA submission
  • Checked 2026-09-01

Limitations and supported-acquisition details reported in the exact-submission ACR model card.

Evidence summary
Study type: Stand-Alone Performance
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Study type: Stand-Alone Performance
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

DM-Density regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K170540
  • IndependenceIndependence not established

K170540

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K170540. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM for-presentation full field digital mammograms from compatible digital mammography systems; validated on Hologic Selenia Dimensions and Lorad Selenia systems.

    Scope: Exact FDA submission. Packet wording: "DM-Density is a standalone software application that automatically analyzes “for presentation” full field digital mammograms to calculate breast tissue composition." … "DM-Density has been validated on Hologic’s Selenia Dimensions and Lorad Selenia systems.". Read from the exact FDA decision document on 2026-11-14.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-11-14 · FDA K170540: DM-Density

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM, PACS, and RIS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · DM-Density model card (K170540)

  3. AI processing

    Source context, not route validation: The exact FDA package describes DM-Density's deployment as a standalone computer, as stated in the 510(k) Submitter column of its comparison-of-characteristics table. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Table 5A – Comparison of Characteristics 510(K) Submitter Predicate" … "Deployment Standalone computer Same N/A Data Throughput 600 cases per hour". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K170540: DM-Density

  4. Returned objects

    Source context, not route validation: For each breast (BI-RADS 4th Ed.): area of fibroglandular tissue (cm²), area of breast (cm²), area-based breast density (%). For each patient (BI-RADS 4th Ed.): DM-Density breast density grade and percent breast density. For each patient (BI-RADS 5th Ed.): DM-Density breast density grade. Output is delivered as a DICOM mammography Structured Report or Secondary Capture viewable on a mammography workstation or PACS, and may also be transmitted to a RIS.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-01 · DM-Density model card (K170540)

  5. Viewer/worklist/report

    Unresolved route: For each breast (BI-RADS 4th Ed.): area of fibroglandular tissue (cm²), area of breast (cm²), area-based breast density (%). For each patient (BI-RADS 4th Ed.): DM-Density breast density grade and percent breast density. For each patient (BI-RADS 5th Ed.): DM-Density breast density grade. Output is delivered as a DICOM mammography Structured Report or Secondary Capture viewable on a mammography workstation or PACS, and may also be transmitted to a RIS.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-01 · DM-Density model card (K170540)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes DM-Density's deployment as a standalone computer, as stated in the 510(k) Submitter column of its comparison-of-characteristics table. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Table 5A – Comparison of Characteristics 510(K) Submitter Predicate" … "Deployment Standalone computer Same N/A Data Throughput 600 cases per hour". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM, PACS, and RIS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Training
The 510(k) summary states that users must be qualified medical practitioners and exercise their professional judgment when formulating diagnostic decisions and selecting appropriate treatment paths supported by breast density estimates.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: Hologic/Lorad

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for DM-Density; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K170540
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-02-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-08Last searched
22Fields reviewed
9Source classes checked
20Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR and official vendor material provide bounded catalog or product-family context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 20 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Care setting: Not yet reviewed - checked 2026-08-31 - Exact FDA submission

    Confirm the intended care setting, patient population, and service line.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K170540 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 2 history items

Source ledger

  1. FDA K170540: DM-Density

    U.S. Food and Drug Administration - Published 2018-02-23 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. DM-Density model card (K170540)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K170540

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K170540 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history